RxDoctor Payments Data

Nishiena Gandhi, MD

Neurology · Albuquerque, NMNPI 1669527438

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 74.9% of it on its own, with 7 other manufacturers making up the rest.

$878in general payments, 2019–2025

Across 48 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$658
  • Teva Pharmaceuticals USA, Inc.$83
  • Biogen$50
  • Novartis$24
  • Eisai Inc.$19
  • Bristol Myers Squibb$16
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$878 in reported general payments places this provider in the 55th percentile of 91 neurology providers in New Mexico.

See all neurology providers in New Mexico

Medicare billing

Part B allowed, 2024
$179,328
Medicare patients
275
Services billed
10,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a28$250,646
CopaxoneGlatiramer Acetate28$160,634
Avonex (4 Pack)Interferon Beta-1a13$107,244
GlatopaGlatiramer Acetate11$64,627
Nurtec OdtRimegepant Sulfate47$60,224
Aimovig AutoinjectorErenumab-Aooe74$55,716
Teriflunomide31$53,869
Rasagiline Mesylate172$31,958
Gabapentin1,053$15,220
Carbidopa-LevodopaCarbidopa/Levodopa517$14,004
Emgality PenGalcanezumab-Gnlm18$12,071
Pregabalin581$9,486
Emgality SyringeGalcanezumab-Gnlm13$9,386
Baclofen521$7,622
Levetiracetam306$6,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$83$160,63428 claims
BiogenAvonex (4 Pack)$50$107,24413 claims
PfizerNurtec Odt$15$60,22447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 91 neurology providers in New Mexico.

Other neurology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →